MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation

详细信息    查看全文

• 作者：Yuan-Ke Liang^a ; ^b ; ^c ; ¹ ; De Zeng^b ; ^d ; ¹ ; Ying-Sheng Xiao^a ; ^b ; Yang Wu^a ; ^b ; Yan-Xiu Ouyang^b ; Min Chen^b ; Yao-Chen Li^b ; Hao-Yu Lin^e ; Xiao-Long Wei^f ; Yong-Qu Zhang^a ; ^b ; Frank A.E. Kruyt^c ; ^{f.a.e.kruyt@umcg.nl} ; Guo-Jun Zhang^a ; ^b ; ^{guoj_zhang@yahoo.com}
• 关键词：Breast cancer ; Tamoxifen resistance ; MCAM/CD146 ; ERα ; AKT pathway
• 刊名：Cancer Letters
• 出版年：2017
• 出版时间：1 February 2017
• 年：2017
• 卷：386
• 期：Complete
• 页码：65-76
• 全文大小：4481 K
• 卷排序：386

文摘

MCAM/CD146 is highly up-regulated and ERα is decreased in MCF-7 breast cancer cells resistance to tamoxifen. MCAM overexpression promotes epithelial mesenchymal transition and activates AKT pathway. The elevated MCAM expression is significantly associated with poorer prognosis in ERα positive breast cancer.